Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK.

Bruton's tyrosine kinase (BTK) has been shown to play a key role in the pathogenesis of autoimmunity. Therefore, the inhibition of the kinase activity of BTK with a small molecule inhibitor could offer a breakthrough in the clinical treatment of many autoimmune diseases. This Letter describes the discovery of BMS-986143 through systematic structure-activity relationship (SAR) development. This compound benefits from defined chirality derived from two rotationally stable atropisomeric axes, providing a potent and selective single atropisomer with desirable efficacy and tolerability profiles.

[1]  Stanley B. Cohen,et al.  Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial , 2020, Arthritis & rheumatology.

[2]  D. Grasela,et al.  Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants , 2020, British journal of clinical pharmacology.

[3]  E. G. Funhoff,et al.  Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. , 2020, Journal of medicinal chemistry.

[4]  E. Hur,et al.  Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study , 2019, Rheumatology and Therapy.

[5]  M. Camps,et al.  Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. , 2019, Journal of medicinal chemistry.

[6]  D. Arnold,et al.  Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. , 2019, The New England journal of medicine.

[7]  Michael A. Galella,et al.  Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK). , 2019, Journal of medicinal chemistry.

[8]  Christian Goess,et al.  ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation , 2018, Modern rheumatology.

[9]  Adam R. Johnson,et al.  Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. , 2018, Journal of medicinal chemistry.

[10]  J. Funk,et al.  A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers , 2017, British journal of clinical pharmacology.

[11]  Sun Ku Lee,et al.  Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants , 2017, European Journal of Clinical Pharmacology.

[12]  E. Winton,et al.  Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. , 2017, Future oncology.

[13]  K. McIntyre,et al.  Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177). , 2016, Journal of medicinal chemistry.

[14]  E. Lee,et al.  HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis , 2016, Arthritis Research & Therapy.

[15]  L. Crofford,et al.  The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy , 2016, Expert review of clinical immunology.

[16]  Y. Iwasawa,et al.  OP0075 TAS5315, A Novel Bruton's Tyrosine Kinase (BTK) Inhibitor, Demonstrates Potent Efficacy in Mouse Collagen-Induced Arthritis Model , 2015 .

[17]  Jason M. Edmonds,et al.  Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis , 2013, The Journal of Immunology.

[18]  Juswinder Singh,et al.  Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[19]  Daigen Xu,et al.  RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents , 2012, Journal of Pharmacology and Experimental Therapeutics.

[20]  Brandon J. Bravo,et al.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. , 2011, Nature chemical biology.

[21]  Mauno Vihinen,et al.  Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain , 2009, Immunological reviews.

[22]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[23]  P. Mease.  B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. , 2008, The Journal of rheumatology.

[24]  Mohamed,et al.  Signalling of Bruton's Tyrosine Kinase, Btk , 1999, Scandinavian journal of immunology.

[25]  T. Kurosaki,et al.  A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2 , 1996, The Journal of experimental medicine.

[26]  Norio Miyaura,et al.  Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds , 1995 .

[27]  R. Holmdahl,et al.  Genes on the X chromosome affect development of collagen‐induced arthritis in mice , 1993, Clinical and Experimental Immunology.

[28]  K. Frederiksen,et al.  Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA. , 1982, The Journal of clinical investigation.